For the Inventor, By the Inventor

Enter inventor name

Kennett Square, PA, United States of America

Andrew Paul Combs

USPTO Granted Patents = 127 (Patent Applications = 41)

CIPO Patents = 13 (Patent Applications = 14)

EPO Patents = 30 (Patent Applications = 38)

Average Co-Inventor Count = 3.8

ph-index = 26

Forward Citations = 2,219(Granted Patents)

Forward Citations (Not Self Cited) = 1,228(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Kenneth Square, PA (US) (2021)
Wilmington, DE (US) (2017 - 2023)
Kennett Square, PA (US) (2005 - 2024)

Company Filing History:

Incyte Corporation

Incyte Holdings Corporation

Prelude Therapeutics Incorporated

Ineyte Corporation

5. 1 out of 234

Bristol-myers Squibb Pharma Company

6. 1 out of 3,684

Bristol-myers Squibb Compnay

Incyte Corportion

Prelude Therapeutics Incorporation

Prelude Therapeutis Incorporated

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Cdk Inhibitors

PI3K Inhibitors

Bet Protein Inhibitors

Aminopyrazine Derivatives

Heterocyclic Compounds

Indoleamine 2,3-Dioxygenase

Bcl-2 Inhibitors

Heterocycles

Pharmaceuticals

Crystalline Forms

Modulators

Tricyclic Heterocycles

127 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12486277 - CDK inhibitors and their use as pharmaceuticals (2025-12-02),

2. 12448389 - BRM targeting compounds and associated methods of use (2025-10-21),

3. 12421197 - Aminopyrazine derivatives as PI3K-γ inhibitors (2025-09-23),

4. 12365668 - Aminopyrazine diol compounds as PI3K-y inhibitors (2025-07-22),

5. 12227502 - 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins (2025-02-18),

6. 12201636 - Heterocyclylamines as PI3K inhibitors (2025-01-21),

7. 12173006 - Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor (2024-12-24),

8. 12152033 - Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders (2024-11-26),

9. 12129262 - CDK inhibitors and their use as pharmaceuticals (2024-10-29),

10. 12030885 - Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors (2024-07-09),

11. 12006320 - Heterocyclic derivatives as PI3K inhibitors (2024-06-11),

12. 11999751 - Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors (2024-06-04),

13. 11952367 - Pyridine and pyridimine compounds as PI3K-gamma inhibitors (2024-04-09),

14. 11939340 - CDK inhibitors and their use as pharmaceuticals (2024-03-26),

15. 11926630 - Tertiary alcohols as PI3K-γ inhibitors (2024-03-12),

Title: The Innovator Behind 115 Patents: Andrew Paul Combs

Introduction: Andrew Paul Combs is a prolific inventor based in Kennett Square, PA (US) with an impressive portfolio of 115 patents to his name. Combs is known for his groundbreaking work in developing compounds that have the potential to revolutionize the treatment of various diseases.

Latest Patents: Among his latest patents, Combs has secured groundbreaking innovations such as "Pyridine and pyridimine compounds as PI3K-gamma inhibitors" and "CDK inhibitors and their use as pharmaceuticals." These patents highlight Combs' expertise in modulating the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and developing pharmaceutical compositions for the treatment of diseases like autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Career Highlights: Combs has made significant contributions to the field of pharmaceuticals through his work at companies like Incyte Corporation and Incyte Holdings Corporation. His innovative approach to drug development has led to the creation of novel compounds that have the potential to improve the lives of patients worldwide.

Collaborations: Throughout his career, Combs has collaborated with esteemed colleagues such as Richard B Sparks and Eddy W Yue. These partnerships have been instrumental in driving forward innovative research and development initiatives in the pharmaceutical industry.

Conclusion: Andrew Paul Combs stands as a prominent figure in the world of inventors, with a remarkable track record of 115 patents to his credit. His innovative work in developing compounds for the treatment of various diseases showcases his dedication to advancing healthcare through cutting-edge research and development.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…